(n = 3) cited budgetary constraints, while only 3% (n = 2) pinpointed health authority requirements to prescribe a cheaper agent first (Figure 6 ).
do not prescribe such a drug to any of their EGFRmutated NSCLC patients first line. More than half of these 23% cited a requirement for treatment before mutation test results are known as their primary reason for not prescribing an EGFR TKI. Just 5% (n = 3) cited budgetary constraints, while only 3% (n = 2) pinpointed health authority requirements to prescribe a cheaper agent first ( Figure 6 ).
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• However, certain country-specific cost-containment policies do have a notable impact on prescribing.
-Approximately three quarters of hematologists and medical oncologists surveyed in Italy reported that the national oncology drugs register monitoring of the use of costly drugs "somewhat" or "severely" restricts their prescribing of premium-priced agents for CML and NSCLC ( Figure 7 ).
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-Approximately one fifth of hematologists and medical oncologists surveyed in Germany reported that their Richtgrößen (indicative prescribing budget) prevents them from prescribing Iclusig® (ponatinib) and Xalkori® (crizotinib) to more than 20% of their CML and NSCLC patients, respectively ( Figure 8 ).
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Discussion
• The cost-constrained EU5 healthcare authorities can no longer afford to provide funding for all novel agents that pharma produces.
-Therefore, the HTA bar is rising steeply, with payers seeking innovation and demonstrable advantages over currently available therapies when assessing novel agents.
-Well-designed clinical trials showing robust survival benefits over suitable comparators, head-to-head, will help optimize P&R conditions.
• Demonstration of cost-effectiveness is imperative.
-The UK is actively entering a new era of valuebased assessment; however, the key elements of this practice are evident across the EU5, perhaps most notably in France, where new brands attaining favorable HTA ratings are now required to undergo pharmacoeconomic evaluation.
-Manufacturers must ensure that their novel agents can stand up to thorough cost-benefit and costeffectiveness analysis. Downstream cost savings can be a key market access lever in this regard. For example, an agent that reduces complications or the need for hospitalization will provide an overall economic benefit, as will improvements in quality of life.
-A strongly predictive biomarker and highly predefined target population are compelling market access tools.
-Developers should identify patients most likely to benefit from targeted treatment, designing earlyphase clinical trials with prospective biomarker analyses and ensuring that pivotal studies select a biomarker showing a robust correlation with the clinically relevant end point.
-Companion diagnostic tests that use surrogate samples, such as serum, plasma, bronchial alveolar lavage, and fine needle aspirates, could improve uptake of targeted agents.
-Furthermore, easy access to tests that provide a higher rate of definitive results more quickly than current tests could be an additional lever, given that need for treatment before test results are obtained was the primary reason for surveyed oncologists not using an EGFR TKI first line for EGFR-mutated NSCLC.
• Well-designed, easily administered cost-sharing schemes can be a powerful bargaining tool in P&R negotiations, and an important prescribing differentiator thereafter.
-Such schemes must be tailored to country-specific preferences. In Italy, payment-by-results schemes are popular, but in the UK straight discounts on list price are preferred due to their reduced administrative burden. At the local level, details of cost-sharing schemes are far less well known than for those in place at national level. It is, however, clear that offering substantial discounts to hospitals initially can help ensure long-term market access.
-As cost-sharing schemes become more prevalent, funding of diagnostic testing, where appropriate, could be an additional lever, country-specific legal requirements permitting.
• Effective marketing strategies educating payers and prescribers on the key benefits that new drugs offer will maximize rapid formulary inclusion.
-Surveyed oncologists reported substantial delays between marketing authorization at pan European level, and availability of drugs for prescribing, especially in the federal healthcare markets of Italy, Spain, and the UK. Targeting payers and prescribers at regional and local levels early in marketing campaigns could help reduce this lag, and also encourage physicians to more willingly accept the administrative burden associated with prescribing more costly agents (e.g. those subject to online monitoring in Italy).
-Manufacturer estimates of patient population size can aid local budget planning (including indicative prescribing budgets in Germany), further encouraging speedy formulary inclusion and uptake.
Background
• Healthcare budgets are increasingly tight across the EU5 (France, Germany, Italy, Spain, and the UK), and payers are exerting ever greater control over prescribing.
• As each country strives to draw out value for money as budgets are being restricted, the health technology assessment (HTA) bar is rising, and cost-containment measures can be aggressive. Consequently, navigating the road to reimbursement, negotiating price premiums, and optimizing uptake is far from straightforward.
• Drawing on insights from surveyed oncologists and interviewed payers, this study explores the impact of HTA, pricing and reimbursement (P&R), and prescribing challenges on market access for current and emerging branded products for non-small-cell lung cancer (NSCLC) and chronic myelogenous leukemia (CML) in the EU5.
Objectives
• To identify the key market access challenges for NSCLC and CML branded products in the EU5, and make actionable recommendations on how to tackle these challenges.
Methods
• Members of national, regional and/or hospital committees in each of the EU5 (n = 6 per country) that influence reimbursement decisions were interviewed regarding their views about the relative importance of clinical versus other factors (e.g., cost) when considering reimbursement and formulary inclusion status for branded products for NSCLC and CML.
• Medical and hematological oncologists across the EU5
were surveyed regarding current and emerging branded products for NSCLC and CML, respectively: 
Results
• Interviewed payers across the EU5 stressed the importance of optimizing clinical trial design in order to secure positive HTA ratings and favorable P&R conditions (Figure 1 ).
-The lack of head-to-head data from pivotal trials of key drugs for NSCLC and CML was criticized in HTA. Payers explained that direct comparator data are vital to adequately demonstrate added benefit over existing agents. Furthermore, the need for careful selection of the most appropriate comparator was highlighted.
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-Payers also underlined the enduring importance of demonstrating superior overall survival, reporting that this remains the gold standard in order for a price premium to be attained for oncology agents. In this regard, cross-over and open-label trials are largely viewed negatively, as true differences in overall survival can be difficult to ascertain in such studies.
-The ability to effectively target a well-defined patient population by means of a strongly predictive biomarker was also flagged as a key lever in HTA and P&R negotiations. This provides greater opportunity for more robust efficacy data, which in turn supports premium pricing. Furthermore, several interviewed payers reported that the ability to identify patients most likely to respond to a given treatment is highly appealing because it means precious funds are less likely to be wasted on those for whom treatment ultimately does not prove beneficial.
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• The growing preference for health outcomes and pharmacoeconomic data in value dossiers for oncology agents was heavily emphasized by payers in all EU5 countries ( Figure 2 ).
-Tightening budgets at national, regional, and local levels were stressed, and payers warned of moves towards value-based assessment/pricing across the EU5, and, therefore, the need to demonstrate cost effectiveness.
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-Evidence for downstream cost savings was also highlighted by a number of payers as being advantageous in P&R negotiations.
• Interviewed payers in Italy, Spain, and the UK advocate cost-sharing or patient-access schemes as a means of securing reimbursement and optimizing uptake (Figure 3 ).
-Payers in Italy report that payment-by-results schemes are preferred in their country as then they need only pay for patients who respond to the drug.
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-Payers in the UK feel that the administrative burden of collecting payment from manufacturers with such outcome-based schemes is too high. They instead favor straight discounts on list prices.
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-Payers in Spain report increasing use of costsharing schemes at a more localized level than their counterparts in Italy and the UK, cautioning that regional budgetary variation can lead to patient access issues for costly agents.
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• Surveyed medical oncologists report lengthy delays between European Medicines Agency marketing approval and availability of novel cancer agents for prescribing.
-Some 63-83% of respondents in France, Italy, Spain, and the UK, and 44% in Germany estimated that the average time taken by their healthcare authority to review newly approved cancer treatments and settle reimbursement terms delays availability for prescribing by >6 months (Figure 4 ).
-Furthermore, at least three-quarters of respondents in each of Italy, Spain, and in the UK, i.e., the markets where there is regional autonomy, expect regional formulary variation to impact their access to emerging NSCLC drugs "somewhat" or "severely". 
CONCLUSION
The EU5 governments are tightening their healthcare belts. To successfully penetrate these markets, novel oncology agents must demonstrate added benefit over existing therapeutics; head-tohead trials against the most appropriate comparator, robust end points, and a well-defined target population are vital. Furthermore, an economic advantagedirect or indirect -is a key market access lever, and fully educating prescribers on the benefits of novel agents will encourage uptake despite increased payer monitoring and complex costcontainment strategies. Head-to-head trials are vital to demonstrate true efficacy. Manufacturers prefer a meta-analysis or non-inferiority studies. But non-inferiority data can have a 20% margin so it's not so easy for us to assess."
Hospital Pharmacist
We still reimburse everything, but no longer always at an extremely high price. In order to maximize reimbursement price, there must be not only robust efficacy data, but a head-to-head trial, so active comparator, a superiority design, and the right end point."
GBA affiliate
For cancer, the gold standard is overall survival. Superior progression-free survival can be great because overall survival is not always easy to reach. But, to gain a really strong ASMR rating and a price premium, you need overall survival."
Ex Commission de la Transparence member
Biomarkers should be incorporated to try to focus the group of patients who will most benefit. Whether the target population is small or large, with strong biomarkers there is no doubt that the new treatment is much better. However, if it's only slightly better but ten times the price, then it is difficult to incorporate into the system"
Pharmacy Director
Pharmacoeconomic data is increasingly important in France. Given the expense of oncology drugs, it's an advantage if you can present a pharmacoeconomic review."
Head Pharmacist
You should always compare the overall cost. If there is an administration of GCSS or EPO, what would be the side effects and treatment of them? Does it reduce complications or the need for hospitalization? We have to evaluate all costs that are related with a treatment. If there is a clinical benefit, there will be an economic benefit."
AIFA advisor and PTOR member
Regional evaluation committees now determine reimbursement conditions based on a combination of cost and effectiveness; somewhat similar to NICE. What can happen is that the group of patients eligible for treatment can differ between regions."
Pharmacy Director
We've got to be realistic. Should we be spending all this money on a treatment where the outcome is only an extra month of life, when we could use the money for a new pediatric service? If you've increased the overall survival from 10% to 50%, or you can demonstrate superior benefit to patients, then that would have significant clout."
CCG and Acute Trust Advisor

CCG Head of Medicines Management
At the regional level, we are increasingly talking in terms of risk sharing to improve patient access. We have innovative new drugs, but our budget is not growing, and in some cases it's even decreasing. With risk sharing, the immediate benefits for the drug companies may not so high, but by being able to introduce all their new brands, they will surely benefit more ultimately" Cost-sharing facilitates approval and also uptake because it's important for physicians to know that if the patients don't respond to the therapy the cost will be covered. Also AIFA will approve drugs with cost-sharing agreements faster because sharing the risk gives them time to establish in clinical practice the actual degree of response."
AIFA advisor and PTOR member
Schemes such as Iressa's are hard to monitor because response, or lack thereof, is hard to demonstrate so there is a lot of admin. The easiest schemes are just a discount on the list price. I'm commissioning the drug, and if everybody knows we should get X% discount, the hospital couldn't charge me more." 
Pharmacy Director and Regional Formulary Committee Member
